Publication Date:
2013-07-17
Description:
Of all human malignancies, glioblastoma multiforme (GBM) is among the most refractory to existing therapies despite combination approaches of surgical resection, irradiation, and chemotherapy. The median survival is ∼12–14 mo, regardless of the therapeutic intervention. The 5-y survival of patients with a diagnosis of GBM is less than 9.8% (1)....
Print ISSN:
0027-8424
Electronic ISSN:
1091-6490
Topics:
Biology
,
Medicine
,
Natural Sciences in General
Permalink